The Centers for Medicare & Medicaid Services (CMS) waded into the growing debate over the use of value-based pricing of prescription drugs by proposing to test a new model to deliver Medicare Part B drugs – infused cancer therapies, injectable antibiotics, eye care treatments and other treatments administered in a physician's office or hospital outpatient setting.